Skip to content

The Standard Management of HPV Infection

The Standard Mangagement of High-Risk HPV Infection During Follow-up Visits

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03577925
Enrollment
800
Registered
2018-07-05
Start date
2016-10-01
Completion date
2019-06-30
Last updated
2018-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the High-Risk HPV Infection

Brief summary

High-risk human papillomavirus (HR-HPV) infection is a necessary condition in the occurence and development of cervical squamous intraepithelial lesion (SIL) and cervical cancer. There are cases that high-grade SIL (HSIL) and stage IA1 cervical squamous cancer remain or reoccur, or even become more severe after conization. The infection situation of HR-HPV, which plays an important role in the prognosis of cervical lesion, should be consulted in the management and follw-up after conization. It is worthwhile making further study in the specific practical significance of the HR-HPV in the prognosis of cervical lesion, as well as the high-risk factors that influence the prognosis of HR-HPV.

Detailed description

Main purpose:To work out the standard management of HPV infection by following up the HPV infection situation of the patients with high-grade SIL (HSIL) and stage IA1 cervical squamous cancer after conization. Research design:First, to do the retrospective analysis toward the patients who received conization between Jan 2009 to Aug 2016.Second,to do the prospective analysis toward the patients who received conization between Spt 2016 to Aug 2018. Inclusive criteria of study population:The patients who had finished HPV genotype testing before conization;who had never received treatment other than conization;who were histologically diagnosed as HSIL or IA1 cervical squamous cancer;who had not been diagnosed as any cervical diseases before;who were under age 70;who did not have any severe diseases that influence the follow-up. Follow-up methods:to do the follow-up to the target patients by 3,6,9,12,18,24 months after conization. Follow-up contents:the HR-HPV genotype infection before conization;the grade of lesion;the age when received conization;the gravity and parity;the situation of the glands invovement

Interventions

DIAGNOSTIC_TESTHPV genotype test

HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* age not above 70 * histologically diagnosed as HSIL or stage IA1 cervical squamous cancer * received conization in Beijing Obstetrics and Gynecology Hospital * HR-HPV infected without any treatment other than conization * HR-HPV genotype tested before coniztion

Exclusion criteria

* age above 70 * with severe desease that influence the follow-up * received other treatment on cervical lesion * data incompleted * not meet the inclusive criteria

Design outcomes

Primary

MeasureTime frameDescription
The HR-HPV clearance24 monthsThe difference of the HR-HPV clearance between HSIL and stage IA1 cervical squamous cancer

Countries

China

Contacts

Primary ContactYU mei Wu, Doctor
wym597118@163.com86 13701016571

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026